Several newly approved therapies have substantially altered the treatment paradigm for multiple genitourinary cancers. Considering the existence of numerous possible treatment approaches, understanding which treatment attributes are most valued by each patient is crucial to physicians to recommend a cancer-directed treatment.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Benjamin, D. J., Xu, A., Lythgoe, M. P. & Prasad, V. Cancer drug approvals that displaced existing standard-of-care therapies, 2016-2021. JAMA Netw. Open 5, e222265 (2022).
Ver Hoeve, E. S., Ali-Akbarian, L., Price, S. N., Lothfi, N. M. & Hamann, H. A. Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors. Support. Care Cancer 29, 349–358 (2021).
George, D. J. et al. Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC) [abstract]. J. Clin. Oncol. 40 (Suppl. 16), e18757 (2022).
Collins, S. P. et al. Identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapies [abstract]. J. Clin. Oncol. 41 (Suppl. 6), 94 (2023).
Grivas, P. et al. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients. Future Oncol. https://doi.org/10.2217/fon-2022-0767 (2023).
Apolo, A. B. et al. Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: a qualitative interview study with patients, caregivers, and physicians [abstract]. J. Clin. Oncol. 41 (Suppl. 6), 492 (2023).
Battle, D. et al. Patient preferences and expectations of systemic therapy in renal cell carcinoma [abstract]. J. Clin. Oncol. 38 (Suppl. 15), 5083 (2020).
Vass, C. et al. Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis [abstract]. J. Clin. Oncol. 41 (Suppl. 6), 661 (2023).
A.R.K. declares stock and other ownership interests: ECOM Medical; consulting or advisory role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics and Gilead Sciences; speakers’ bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences and AVEO; research funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics and Epizyme; and travel, accommodations and/or expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis and AstraZeneca. D.J.B. declares no competing interests.
About this article
Cite this article
Benjamin, D.J., Rezazadeh Kalebasty, A. Patient preferences in the treatment of genitourinary cancers. Nat Rev Urol 20, 513–514 (2023). https://doi.org/10.1038/s41585-023-00765-8